Ernexa Therapeutics (ERNAW) Research & Development (2020 - 2026)

Ernexa Therapeutics has reported Research & Development for 7 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 46.29% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (up 6.89% YoY), and the FY2025 full-year result was $4.2 million, down 9.73% from the prior year.
• Research & Development for Q1 2026 stood at $1.9 million, up from $676000.0 in the prior quarter.
• The five-year high for Research & Development was $3.5 million in Q3 2022, with the low at $676000.0 in Q4 2025.
• Historically, Research & Development has averaged $1.5 million across 5 years, with a median of $1.4 million in 2023.
• The largest YoY upside for Research & Development was 134.74% in 2022 against a maximum downside of 68.98% in 2022.
• Ernexa Therapeutics' Research & Development stood at $2.0 million in 2022, then slumped by 30.68% to $1.4 million in 2023, then retreated by 14.85% to $1.2 million in 2024, then plunged by 41.62% to $676000.0 in 2025, then soared by 183.28% to $1.9 million in 2026.
• The last three Research & Development figures came in at $1.9 million (Q1 2026), $676000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.